Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum eFFECTOR Therapeutics Inc EFTR

Healthcare Biotechnology
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and... see more

Bullboard (NDAQ:EFTR)

View:
Post by Iseneschalon Apr 04, 2024 9:16am

EFTR....darn near killed 'er! NR this a.m....crash

  eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer   2024-04-04 05:30 PT - News ...more  
27
Post by whytestockson Jan 25, 2024 6:45pm

eFFECTOR Therapeutics Announces $15 Million Registered Direc

NEWS: $EFTR eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | BenzingaSOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE ...more  
46
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities